Genomic data from a pharmacogenetic study based on the efficacy of Tocilizumab in severe COVID-19 patients
- Rego-Perez, Ignacio
- Alejandro, Durán-Sotuela
- Jorge, Vázquez-García
- Sara, Relaño-Fernández
- Vanesa, Balboa-Barreiro
- Juan, Fernández-Tajes
- Francisco J, Blanco
DOI:
10.5281/ZENODO.13692512
lock_openOpen access editor
Abstract
These data correspond to a pharmacogenetic study aimed to explore genetic associations related to the efficacy of Tocilizumab in severe COVID-19 patients. The study comprised two sets of patients, an initial subset consisted of 425 patients to whom a in-dpeth sequencing of a thermofisher sequencing panel of immune-related genes was performed, as well as a second set of 245 patients with the information of the genotyping of three selected SNPs